Clinical Trials Logo

Central Precocious Puberty (CPP) clinical trials

View clinical trials related to Central Precocious Puberty (CPP).

Filter by:
  • None
  • Page 1

NCT ID: NCT03695237 Completed - Clinical trials for Central Precocious Puberty (CPP)

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Start date: October 24, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.

NCT ID: NCT00667446 Completed - Clinical trials for Central Precocious Puberty (CPP)

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Start date: December 2008
Phase: Phase 3
Study type: Interventional

The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).